Frontotemporal lobar degeneration with tau pathology (FTLD-tau) encompasses a heterogeneous group of neurodegenerative diseases that share tau protein aggregation as a central pathogenic mechanism. Despite sharing this common endpoint, FTLD-tau subtypes differ markedly in their molecular signatures, histological lesion morphology, cellular distribution, clinical presentation, and genetic architecture. This page provides a systematic comparison of the major FTLD-tau subtypes: [Pick's disease](/diseases/pick-disease) (3R), [corticobasal degeneration](/diseases/corticobasal-degeneration) (4R), [progressive supranuclear palsy](/diseases/psp) (4R), [argyrophilic grain disease](/diseases/argyrophilic-grain-disease) (4R), and [globular glial tauopathy](/diseases/globular-glial-tauopathy) (4R). [@karimov2022] [@dickson2023]
The MAPT gene on chromosome 17q21.31 encodes the microtubule-associated protein tau (MAPT). Alternative splicing of exons 2, 3, and 10 produces six isoforms in the adult human brain, categorized by the presence of three (3R) or four (4R) microtubule-binding repeat domains. This fundamental molecular distinction divides FTLD-tau into 3R-predominant and 4R-predominant subtypes, each with distinct pathobiology. [@goedert2017] [@araki2021]
```mermaid
flowchart TB
subgraph FTLDTau["FTLD-Tau Spectrum"]
direction TB
subgraph Sub3R["3R Tauopathies"]
A1["Pick's Disease<br/>(PiD)"]
end
Frontotemporal lobar degeneration with tau pathology (FTLD-tau) encompasses a heterogeneous group of neurodegenerative diseases that share tau protein aggregation as a central pathogenic mechanism. Despite sharing this common endpoint, FTLD-tau subtypes differ markedly in their molecular signatures, histological lesion morphology, cellular distribution, clinical presentation, and genetic architecture. This page provides a systematic comparison of the major FTLD-tau subtypes: [Pick's disease](/diseases/pick-disease) (3R), [corticobasal degeneration](/diseases/corticobasal-degeneration) (4R), [progressive supranuclear palsy](/diseases/psp) (4R), [argyrophilic grain disease](/diseases/argyrophilic-grain-disease) (4R), and [globular glial tauopathy](/diseases/globular-glial-tauopathy) (4R). [@karimov2022] [@dickson2023]
The MAPT gene on chromosome 17q21.31 encodes the microtubule-associated protein tau (MAPT). Alternative splicing of exons 2, 3, and 10 produces six isoforms in the adult human brain, categorized by the presence of three (3R) or four (4R) microtubule-binding repeat domains. This fundamental molecular distinction divides FTLD-tau into 3R-predominant and 4R-predominant subtypes, each with distinct pathobiology. [@goedert2017] [@araki2021]
The human [tau](/proteins/tau-protein) gene contains 16 exons, with exons 2, 3, and 10 subject to alternative splicing. Inclusion of exon 10 adds a fourth microtubule-binding repeat (R1-R4), producing 4R isoforms; exclusion produces 3R isoforms (lacking the N-terminal portion of R2). In the normal adult human brain, 3R and 4R tau isoforms are present in approximately equal proportions. [@goedert2003] [@bhangare2022]
The microtubule-binding repeat domain (R1-R4) is the primary driver of tau aggregation. The hexapeptide motifs306-VQIVYK-311 and378-VQIVTK-383 within the repeat domain form the β-strand core of tau fibrils. In 4R tauopathies, inclusion of the R2 domain (encoded by exon 10) confers enhanced aggregation propensity and altered filament morphology. [@fitzpatrick2017]
| Property | 3R Tau | 4R Tau |
|----------|--------|--------|
| Microtubule binding affinity | Moderate | Higher (due to extra R2 repeat) |
| Aggregation propensity | Lower baseline | Higher baseline |
| Filament structure | Distinct folds (Pick-type) | Distinct folds (PSP/CBD/AGD-type) |
| Normal brain ratio | ~50% of total tau | ~50% of total tau |
| Disease association | Pick's disease (primary) | PSP, CBD, AGD, GGT |
| Genetic risk | MAPT mutations affecting exon 10 splicing | H1 haplotype (PSP, CBD), MAPT missense mutations |
MAPT mutations in FTLD-tau fall into two broad categories: splicing mutations that disrupt the 3R/4R balance (primarily affecting exon 10), and missense mutations within the microtubule-binding repeats that impair microtubule binding or promote aggregation. Splicing mutations typically produce 4R tauopathies (increased exon 10 inclusion), while missense mutations can produce either 3R or 4R pathology depending on their location. [@schofield2012]
The H1 haplotype of MAPT (present in >95% of sporadic PSP cases) is the major genetic risk factor for sporadic 4R tauopathies. The H2 haplotype appears protective. These haplotypes influence MAPT transcription, splicing, and possibly the efficiency of tau mRNA degradation. [@dickson2023]
| Feature | Pick's Disease (PiD) | Corticobasal Degeneration (CBD) | Progressive Supranuclear Palsy (PSP) | Argyrophilic Grain Disease (AGD) | Globular Glial Tauopathy (GGT) |
|---------|---------------------|-------------------------------|--------------------------------------|--------------------------------|-------------------------------|
| Tau isoform | 3R predominant | 4R predominant | 4R predominant | 4R predominant | 4R predominant |
| Primary lesion | Pick bodies (neurons) | Astrocytic plaques (astrocytes) | Tufted astrocytes (astrocytes) | Argyrophilic grains (neurons/glia) | Globular oligodendroglial inclusions (GOIs) |
| Key histological features | Pick bodies, ballooned neurons, cortical blindness | Asymmetric cortical atrophy, astrocytic plaques, neuronal loss | Tufted astrocytes, coiled bodies, NFT in brainstem | Argyrophilic grains, pretangle pathology, enlarged neurons | Globular inclusions in oligodendrocytes (GOIs) and astrocytes (GAIs) |
| Cellular distribution | Neurons > glia | Astrocytes prominent, neurons, oligodendrocytes | Astrocytes, neurons, oligodendrocytes | Neurons and glia | Oligodendrocytes (GOIs) and astrocytes (GAIs) |
| Filament structure (cryo-EM) | Three-helix fold, distinct from AD | Two-protofilament fold, distinct from PSP/AD | Two-protofilament fold, distinct from CBD/AD | Two-protofilament fold, distinct from CBD/AD | Distinct from PSP and CBD |
| Typical onset age | 40-65 years | 50-70 years | 55-70 years | 60-80 years | 50-75 years |
| Clinical phenotype | FTD (behavioral/language), rapid progression | CBS, asymmetric rigidity, apraxia, alien limb | PSP syndromes (vertical gaze palsy, falls, parkinsonism) | Late-onset dementia with memory/behavioral changes | FTD-ALS spectrum, bvFTD, motor neuron disease |
| Motor involvement | Variable | Prominent (parkinsonism, dystonia, myoclonus) | Prominent (axial rigidity, gaze palsy) | Mild | Often prominent (ALS/PLS features) |
| MAPT mutations | Some familial cases | Rare (usually 4R) | H1 haplotype strong risk; rare mutations | H1 haplotype risk | Rare (4R) |
| Other genetic risk | Unknown | GRN, TMEM106B | H1/H1 haplotype | Unknown | Unknown |
| Diagnostic biomarkers | CSF p-tau181, tau PET | NfL, tau PET (limited) | NfL, CSF p-tau231, tau PET | Limited | Limited |
Pick's disease is the prototypical 3R tauopathy, characterized neuropathologically by the presence of Pick bodies — round to oval, argyrophilic intracytoplasmic inclusions composed predominantly of 3R tau isoforms. [@sergeant2005] Cryo-EM studies have revealed that Pick body filaments adopt a three-helix fold distinct from the two-protofilament folds observed in [Alzheimer's disease](/diseases/alzheimers-disease) and 4R tauopathies. [@baikofen2024]
Pick bodies are composed of hyperphosphorylated 3R tau arranged in a paired helical filament-like structure, but structurally distinct from the classic paired helical filaments of AD. The inclusions are tau-positive, ubiquitin-positive, and p62-positive, with variable TDP-43 co-pathology in some cases. [@dickson2023]
The classic triads of Pick's disease include: [@goedert2003]
Pick's disease typically presents with the behavioral variant of [frontotemporal dementia](/diseases/ftd) (bvFTD) or primary progressive aphasia variants. The clinical phenotype reflects frontotemporal neurodegeneration: [@karimov2022]
[Corticobasal degeneration](/diseases/corticobasal-degeneration) is a 4R tauopathy with a characteristic asymmetric distribution of pathology. Cryo-EM studies have shown that CBD filaments adopt a two-protofilament fold that is distinct from both [Alzheimer's disease](/diseases/alzheimers-disease) and [progressive supranuclear palsy](/diseases/psp) filaments, despite both being 4R tauopathies. [@fitzpatrick2017] [@kovacs2020cbd]
The 4R tau in CBD is hyperphosphorylated at multiple epitopes (AT8, AT100, PHF-1) and forms distinct ultrastructural filaments that differ in their protofilament packing from PSP. This structural distinction may explain the clinical and pathological heterogeneity between these disorders. [@baikofen2024]
The characteristic lesions of CBD include: [@dickson2019] [@armstrong2020]
The classic clinical presentation of corticobasal degeneration is corticobasal syndrome (CBS): [@armstrong2020]
[Progressive supranuclear palsy](/diseases/psp) is the most common 4R tauopathy and the most frequent neurodegenerative cause of atypical parkinsonism. The H1 MAPT haplotype is present in over 95% of sporadic cases, making it the strongest genetic risk factor in neurodegeneration. [@kovacs2020psp] [@josephs2019]
Cryo-EM studies have revealed that PSP tau filaments adopt a two-protofilament fold that is distinct from CBD filaments, despite both being 4R tauopathies with similar ultrastructural features under conventional EM. The structural differences in protofilament packing correlate with the distinct clinical phenotypes and neuropathological lesion types of these two disorders. [@baikofen2024]
The hallmark lesions of PSP include: [@kovacs2020psp]
The classic presentation is the Richardson syndrome (PSP-Richardson syndrome): [@josephs2019]
[Argyrophilic grain disease](/diseases/argyrophilic-grain-disease) is a 4R tauopathy characterized by the presence of argyrophilic grains — spindle-shaped, argyrophilic inclusions in neuronal processes and dendrites. AGD is increasingly recognized as a common contributor to late-onset dementia, often co-existing with AD-type amyloid pathology. [@tolnay2022]
Like CBD and PSP, AGD tau filaments adopt a two-protofilament fold, but structural studies suggest subtle differences in protofilament packing that may account for the distinct grain-like morphology. [@baikofen2024]
The characteristic lesions of AGD include: [@tolnay2022]
AGD typically presents as a late-onset dementia with prominent behavioral and memory features: [@tolnay2022] [@schweighofer2023]
[Globular glial tauopathy](/diseases/globular-glial-tauopathy) is a rare 4R tauopathy distinguished by globular inclusions in both oligodendrocytes and astrocytes, with oligodendroglial pathology predominating. The condition was unified under the GGT nomenclature in 2013 and represents a distinct entity within the 4R tauopathy spectrum. [@ahmed2013]
The globularity of the inclusions (spherical, well-circumscribed, displacing the nucleus peripherally) distinguishes them from the crescent-shaped coiled bodies of PSP and the annular astrocytic plaques of CBD. [@deller2019]
Three neuropathological subtypes are recognized based on regional distribution: [@ahmed2013]
The defining lesions are: [@deller2019]
GGT typically presents with: [@deller2019] [@kovacs2018]
Cryo-electron microscopy has revolutionized the understanding of tauopathies by revealing distinct filament folds across diseases. These structural differences provide a molecular basis for the observed pathological and clinical heterogeneity. [@fitzpatrick2017] [@baikofen2024]
| Tauopathy | Filament Fold | Protofilament Architecture | C-Terminal Conformation |
|-----------|---------------|--------------------------|------------------------|
| Alzheimer's disease | Two-protofilament, helical | Asymmetric, L-shaped | Folded back |
| Pick's disease | Three-helix fold | Novel compact fold | Extended |
| CBD | Two-protofilament | Distinct packing from PSP | Folded back |
| PSP | Two-protofilament | Distinct packing from CBD | Folded back |
| AGD | Two-protofilament | Related to PSP/CBD but distinct | Folded back |
| GGT | Distinct | Different from PSP and CBD | Under characterization |
The structural differences between CBD and PSP filaments — despite both being 4R tauopathies with similar appearance under conventional electron microscopy — explain the distinct histological lesion types (astrocytic plaques vs. tufted astrocytes) and clinical phenotypes. These structural differences also have implications for biomarker development and therapeutic targeting, as conformation-specific antibodies and PET ligands may be able to distinguish between these entities. [@baikofen2024]
A distinguishing feature of 4R tauopathies is the prominence of glial tau pathology, which varies in morphology, cellular distribution, and anatomical distribution across subtypes. This represents a key differential feature. [@deller2019]
| Glial Feature | Pick's Disease | CBD | PSP | AGD | GGT |
|---------------|---------------|-----|-----|-----|-----|
| Astrocytic tau | Rare | Prominent (plaques) | Prominent (tufted) | Moderate (thorn-shaped) | Moderate (GAIs) |
| Oligodendroglial tau | Rare | Moderate (coiled bodies) | Moderate (coiled bodies) | Moderate (coiled bodies) | Very prominent (GOIs) |
| Astrocyte morphology | Ballooned neurons predominant | Annular/wreath plaques | Tufted perinuclear | Thorn-shaped | Globular spherical |
| Oligodendrocyte morphology | Minimal involvement | Crescents/coiled | Crescents/coiled | Crescents/coiled | Large spherical globules |
| White matter involvement | Mild | Moderate | Moderate | Moderate | Severe |
Despite their clinical and pathological differences, all FTLD-tau subtypes share several core pathogenic mechanisms: [@karimov2022] [@schweighofer2023]
| Mechanism | 3R Tauopathies (Pick's) | 4R Tauopathies |
|-----------|------------------------|----------------|
| Isoform affected | 3R predominates | 4R predominates |
| Primary cellular target | Neurons | Astrocytes and oligodendrocytes prominent |
| Aggregation propensity | Moderate | High (extra R2 repeat) |
| Filament fold | Three-helix compact | Two-protofilament extended |
| Clinical phenotype | FTD behavioral/language | Parkinsonism (PSP), CBS, dementia |
| H1 haplotype risk | Weaker | Very strong |
| Typical progression | Rapid | Slower, more varied |
The distinct molecular signatures of FTLD-tau subtypes have important implications for therapeutic development. Tau-targeted therapies under investigation include: [@bhangare2022]